Scientists have discovered a previously unknown cellular barrier in the brain's choroid plexus, named "base barrier cells." The cells form a dynamic seal that can be compromised during systemic inflammation, offering new insights into brain protection and potential therapeutic targets for neurological disorders.
Cerebral organoids are revealing how Ebola virus persists, aiding treatment research for rare Parkinson's disease, modeling Alzheimer's, and gaining whole-network recording capabilities.
NeuroSense Therapeutics reported that its ALS drug PrimeC achieved a statistically significant 65% reduction in the risk of death in a Phase 2b trial. Separately, the company was granted a South Korean patent covering PrimeC's composition, formulation, and use for ALS treatment through 2042.
The EMA’s CHMP recommended approval of Sanofi’s Cenrifki (tolebrutinib) for non-relapsing secondary progressive multiple sclerosis. The phase 3 HERCULES study showed reduced disability progression, while liver injury remains an identified safety risk.
CervoMed presents new MRI data showing neflamapimod may reduce basal forebrain atrophy in dementia with Lewy bodies and finalizes Phase 3 trial design. The drug has also been selected for a UK-funded ALS platform trial, with first dosing expected by end of 2026.
New research reveals significant advances in blood-based biomarkers for Alzheimer's disease, including a pTau 217 assay showing 93% agreement with amyloid PET imaging and identification of interferon gamma as a diagnostic signal linked to genetic risk. These developments address challenges in early diagnosis and monitoring while requiring substantially less plasma than previous tests.
Recent research identifies novel genetic causes for rare movement and neurodegenerative disorders, including CD99L2 variants in spastic ataxia, PPP2R5C as an Alzheimer's biomarker, and toxic polyglycine proteins in GGC repeat expansion diseases.
Coya Therapeutics detailed plans for a Phase 2 trial of combination immunotherapy targeting neuroinflammation in ALS, following a four-patient study showing biomarker improvements and reported slowing of disease progression.
Polaryx Therapeutics has selected a contract research organization to conduct SOTERIA, a phase 2 trial evaluating PLX-200 across four rare lysosomal storage disorders, with trial initiation planned for the first half of 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07782411 |
Effect of Tocopherol and Ascorbic Acid on Neuroinflammation Markers Associated With Neuropeptide Expression in the AgRP/NPY and POMC Pathways in Mexican Population With Obesity |
NOT_YET_RECRUITING | NA |
| NCT07671040 |
A Pilot Study of Adjunctive Structured Supportive Psychotherapy in Schizophrenia |
COMPLETED | NA |
| NCT07644065 |
Kynurenic Acid and Serotonin as Perioperative Neuroinflammatory Biomarkers in Sequential Third Molar Surgery |
COMPLETED | NA |
| NCT07575516 |
Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone |
COMPLETED | PHASE2 |
| NCT07269457 |
Vitamin D3 for Moderate to Mild Traumatic Brain Injury: A Randomized Trial on Inflammation and Recovery (VIMOT) |
RECRUITING | PHASE2 |
| NCT05350774 |
Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2 |
ENROLLING_BY_INVITATION | PHASE2 |
| NCT04814355 |
The Effect of Celecoxib on Neuroinflammation in MDD |
COMPLETED | PHASE4 |
